抗炎性败血性休克的 ангиотензин ii 治疗:哪个患者可以从中获益最多? 一个叙事审查
Irene Coloretti1, Andrea Genovese2, J Pedro Teixeira3
1Anesthesia and Intensive Care Medicine, Policlinico Di Modena, University of Modena and Reggio Emilia, Via del Pozzo, Modena, 71. 41124, Italy. irenecoloretti@gmail.com.
Journal of anesthesia, analgesia and critical care
|February 21, 2024
概括
在败血性休克中,尽管服用高剂量的诺拉丁上腺素,但耐火性低血压是常见的. ангиотензин II 为这些重症患者提供了一个有前途的新疗法,有可能改善治疗结果.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 生理学 生理学 生理学
背景情况:
- 尽管进行了液体复苏和高剂量的诺阿德林林,但患有不耐药性低血压的败血性休克患者面临高死亡率.
- 当前的指导方针建议添加第二个血管压缩剂,如血管压缩剂,当诺拉丁上腺素超过0.5微克/千克/分钟时.
研究的目的:
- 审查血管扩张性休克时的氨酸- ангиотензин系统的病理生理学.
- 探索抗炎性低血压的临床结果和患者群体,这些患者可能受益于血管新素II治疗.
主要方法:
- 现有文献的叙述性审查.
- 讨论内源性 ангиотензин II 的作用.
- 对血管扩张性休克中血管素II的临床试验数据的分析.
主要成果:
- ангиотензин II 已证明在患有血管扩张性休克的患者中提高平均动脉压的有效性.
- 初步数据表明,血管素II治疗改善了临床结果.
- 氨酸- ангиотензин系统在保持在休克期间的血管度方面发挥着至关重要的作用.
结论:
- ангиотензин II 代表了一种有前途的治疗选择,用于耐火性低血压在性休克.
- 需要进一步的研究来确定最佳剂量,并确定特定的患者亚组,这些亚组将获得最大的益处.
- 了解氨酸-血管酶系统的作用是管理复杂冲击状态的关键.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
731
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
731
01:25Antihypertensive Drugs: Direct Renin Inhibitors
629
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
629
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
638
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
638
01:22Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165